(Total Views: 1150)
Posted On: 11/18/2020 6:22:35 AM
Post# of 154710
Dr Bruce Patterson just tweeted a link to what I believe in a newly published peer reviewed paper related to cancer with a mention of Leronlimab.
https://t.co/m3LtxXMOb8?amp=1
Similarly, therapeutics targeting CCR5 have been shown to have anti-tumor and anti-metastatic activity [33]. CCR5 inhibitors such as Maraviroc [Pfizer, Inc], Leronlimab [Cytodyn, Inc], and newer compounds such as OB-002 [Orion Biotechnologies, Inc] are newer additions to the immune-oncology armamentarium. In addition to potentially inhibiting the influx of Treg cells into the tumor, CCR5 inhibitors also have been shown to cause repolarization of macrophages to an anti-tumor phenotype in colorectal cancer
https://t.co/m3LtxXMOb8?amp=1
Similarly, therapeutics targeting CCR5 have been shown to have anti-tumor and anti-metastatic activity [33]. CCR5 inhibitors such as Maraviroc [Pfizer, Inc], Leronlimab [Cytodyn, Inc], and newer compounds such as OB-002 [Orion Biotechnologies, Inc] are newer additions to the immune-oncology armamentarium. In addition to potentially inhibiting the influx of Treg cells into the tumor, CCR5 inhibitors also have been shown to cause repolarization of macrophages to an anti-tumor phenotype in colorectal cancer
(7)
(0)
